Current Report Filing (8-k)
June 26 2019 - 4:07PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
June 20, 2019
Anika Therapeutics, Inc.
(Exact name of registrant as specified
in its charter)
____________________
Delaware
|
000-21326
|
04-3145961
|
(State or other jurisdiction of
incorporation or organization)
|
Commission file number
|
(I.R.S. Employer
Identification No.)
|
32 Wiggins Avenue, Bedford, MA 01730
(Address of principal executive offices)
(Zip code)
(781)-457-9000
Registrant’s telephone number,
including area code:
Not applicable
(Former name or former address, if changed
since last report)
____________________
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[_]
Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425)
[_]
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[_]
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[_]
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock, par value $0.01 per share
|
|
ANIK
|
|
NASDAQ Global Select Market
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange
Act of 1934 (17 CFR §240.12b-2).
Emerging growth company
[_]
If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
[_]
|
Item 5.02.
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers.
|
The employment of Edward S. Ahn, Ph.D., as our Chief Technology
and Strategy Officer will end effective July 5, 2019.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Anika Therapeutics, Inc.
|
|
|
|
|
Date: June 26, 2019
|
By:
|
/s/
Sylvia Cheung
|
|
|
Chief Financial Officer
|
Anika Therapeutics (NASDAQ:ANIK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Anika Therapeutics (NASDAQ:ANIK)
Historical Stock Chart
From Sep 2023 to Sep 2024